Title:
PARP7 INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2022/247839
Kind Code:
A1
Abstract:
The present invention relates to the technical field of medicines, and in particular, to a PARP7 kinase inhibitor compound represented by general formula (I), a pharmaceutically acceptable salt or isomer thereof, a pharmaceutical composition containing the compound and the pharmaceutically acceptable salt or isomer thereof, a method for preparing the compound and the pharmaceutically acceptable salt or isomer thereof, and a use of the compound and the pharmaceutically acceptable salt or isomer thereof.
More Like This:
Inventors:
LIU BIN (CN)
CHEN BO (CN)
TIAN JINLONG (CN)
CHEN BO (CN)
TIAN JINLONG (CN)
Application Number:
PCT/CN2022/094808
Publication Date:
December 01, 2022
Filing Date:
May 25, 2022
Export Citation:
Assignee:
SHANDONG XUANZHU PHARMA CO LTD (CN)
International Classes:
C07D498/14; A61K31/501; A61P35/00; C07D401/14; C07D403/12; C07D471/04
Domestic Patent References:
| WO2020223229A1 | 2020-11-05 | |||
| WO2021087025A1 | 2021-05-06 | |||
| WO2021087018A1 | 2021-05-06 | |||
| WO2019055966A2 | 2019-03-21 |
Foreign References:
| CN112424188A | 2021-02-26 |
Other References:
STRAPPAGHETTI, G. ; CORSANO, S. ; BARBARO, R. ; LUCACCHINI, A. ; GIANNACCINI, G. ; BETTI, L.: "Adenosine receptors: synthesis, structure-activity relationships and biological activity of new 6-amino purine derivatives", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, no. 6, 1 June 1998 (1998-06-01), AMSTERDAM, NL , pages 501 - 508, XP026884003, ISSN: 0223-5234, DOI: 10.1016/S0223-5234(98)80050-0
Download PDF: